Merck Animal Health Canada, Kirkland, Quebec, Canada H9H 4M7,
MSD Santé Animale, 49070 Beaucouzé, France.
Avian Dis. 2021 Jun;65(2):257-260. doi: 10.1637/0005-2086-65.2.257.
A multiage commercial layer pullet operation with a history of chicken embryo-origin (CEO) modified live infectious laryngotracheitis (ILT) virus vaccination suffered severe ILT outbreaks in 2017. The initial sequencing revealed that the circulating virus was of vaccine origin. Changes to the timing and dosage of CEO ILT vaccine failed to control the outbreak. The clinical resolution of the outbreak occurred with the transition to a turkey herpesvirus vector vaccine given in-hatchery, followed by a tissue culture-origin vaccine given on the farm. The circulating ILT viruses were monitored periodically by next-generation sequencing. This site became free of ILT virus within 1 yr after implementing the new vaccination program.
一个具有鸡胚源(CEO)改良活传染性喉气管炎(ILT)病毒疫苗接种史的多日龄商业蛋鸡养殖场在 2017 年遭受了严重的 ILT 暴发。最初的测序结果表明,循环病毒来源于疫苗。改变 CEO ILT 疫苗的接种时间和剂量未能控制疫情。随着在孵化场接种火鸡疱疹病毒载体疫苗,并随后在农场接种组织培养起源的疫苗,疫情得到了临床缓解。通过下一代测序定期监测循环中的 ILT 病毒。在实施新的疫苗接种计划后 1 年内,该场已无 ILT 病毒。